BioMarin Pharmaceutical | BMRN - 普通股股本



金融业
股票价格
USD
资产
USD 11.72B
现金及等价物
USD 874.01M
销售成本
USD 276.29M
流动资产
USD 3.97B
流动负债
USD 1.66B
债务
USD 1.44B
EBIT
USD 105.61M
EBITDA
USD 146.05M
员工
3.04K
EPS每股收益
USD 1.2
股本和储备
USD 6.32B
销售毛利
USD 713.42M
债务利息支出
USD 63.3M
利息收入
USD 22.56M
贷款资金
USD 3.53B
市值
USD 12.29B
净收入
USD 44.76M
营业费用
USD 6.32B
营业利润
USD 105.61M
普通股股本
USD 193.54M
PE价格收益
21.07
税前利润
USD 141.2M
销售收入
USD 990M
销售和管理费用
USD 395.55M
股票
USD 1.78B
贸易债权人
USD 913.67M
应收帐款人
USD 1.06B


普通股股本 更改 日
Acadia Pharmaceuticals USD 171.09M 1.9M 2026-03
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Alnylam Pharmaceuticals USD 133.73M 290K 2026-06
Amgen USD 541M 1000K 2026-06
Bayer EUR 982.42M 0 2026-06
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Gilead Sciences USD 1.24B 1000K 2026-06
Incyte USD 200.98M 1.03M 2026-06
Insmed USD 218.28M 1.76M 2026-06
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
Moderna USD 391M 2M 2025-09
Neurocrine Biosciences USD 100.55M 50K 2026-06
PTC Therapeutics USD 82.88M 1.41M 2026-03
Puma Biotechnology USD 5K 0 2024-06
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Roche Holding CHF 796.77M 1.15M 2026-06
Sanofi EUR 1.2B 16.88M 2026-03
Sarepta Therapeutics USD 105.62M 53K 2026-06
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
United Therapeutics USD 42.68M 521K 2026-06
Vertex Pharmaceuticals USD 253.3M 900K 2026-06